| Bioactivity | FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1]. | ||||||
| Name | FTISADTSK acetate | ||||||
| Shortening | FTISADTSK | ||||||
| Formula | C44H72N10O18 | ||||||
| Molar Mass | 1029.10 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
FTISADTSK acetate
CAS: F: C44H72N10O18 W: 1029.10
FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.